Longitudinal Characterization of Vascular Inflammation and Disease Activity in Takayasu Arteritis and Giant Cell Arteritis: A<scp>Single‐Center</scp>Prospective Study

Alessi, Hugh; Quinn, Kaitlin A.; Ahlman, Mark A.; Novakovich, Elaine; Saboury, Babak; Luo, Yiming; Grayson, Peter C.

doi:10.1002/acr.24976

Cited by 6 publications

(4 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Alessi et al [22 ▪▪ ] evaluated and compared disease activity over time in 50 GCA and 76 TAK patients using multimodal assessment combining clinical, laboratory, and imaging-based testing. Patients underwent standardized assessment, including PET, at enrollment and follow-up visits.…”

Section: Role Of Pet In Assessing Disease Activitymentioning

confidence: 99%

The role of PET/CT in disease activity assessment in patients with large vessel vasculitis

Galli

Pipitone

Salvarani

2023

Current Opinion in Rheumatology

View full text Add to dashboard Cite

Objectives. To evaluate the accuracy of PET/CT and of PET vascular activity score (PETVAS) in assessing disease activity and the ability of PETVAS in predicting relapses in a large single-centre cohort of patients with large vessel vasculitis (LVV).Methods. We conducted a retrospective cohort study of prospectively collected data of consecutive patients diagnosed with LVV who underwent at least one PET/CT scan between 2007 and 2020. The nuclear medicine physician's interpretation of each PET/CT scan (active/inactive vasculitis) was compared with disease activity clinical judgement (active disease/remission). For each PET/CT scan, the PETVAS score was calculated and its accuracy in assessing disease activity was evaluated. The ability of PETVAS in predicting subsequent relapses was evaluated.Results. A total of 100 consecutive LVV patients (51 large vessel GCA, 49 Takayasu arteritis) underwent a total of 476 PET/CT scans over a mean follow-up period of 97.5 months. Physician-determined PET/CT grading was able to distinguish between clinically active and inactive LVV with a sensitivity of 60% (95% CI 50.9, 68.7) and specificity of 80.1% (95% CI 75.5, 84.1); the area under the curve (AUC )was 0.70 (95% CI 0.65, 0.75). PETVAS was associated with disease activity, with an age and sex-adjusted odds ratio for active disease of 1.15 (95% CI 1.11, 1.19). A PETVAS 10 provided 60.8% sensitivity and 80.6% specificity in differentiating between clinically active and inactive LVV; the AUC was 0.73 (95% CI 0.68, 0.79). PETVAS was not associated with subsequent relapses, with an age and sex-adjusted hazard ratio of 1.04 (95% CI 0.97, 1.11).Conclusions. The visual PET/CT grading scale and PETVAS had moderate accuracy to distinguish active LVV from remission. PETVAS did not predict disease relapses.

show abstract

Section: Role Of Pet In Assessing Disease Activitymentioning

confidence: 99%

The role of PET/CT in disease activity assessment in patients with large vessel vasculitis

Galli

Pipitone

Salvarani

2023

Current Opinion in Rheumatology

View full text Add to dashboard Cite

show abstract

“…After a median follow up of 2.6 years, there was no significant decrease in PETVAS in TA patients. Also, there was no direct correlation between PETVAS during follow up and clinical and biological activity ( 73 ).…”

Section: -[18f]fdg-pet/ct and Giant Cell Arteritismentioning

confidence: 99%

18-Fluorodeoxyglucose positron emission tomography/computed tomography for large vessel vasculitis in clinical practice

et al. 2023

View full text Add to dashboard Cite

Diagnosis, prognostic assessment, and monitoring disease activity in patients with large vessel vasculitis (LVV) can be challenging. Early recognition of LVV and treatment adaptation is essential because vascular complications (aneurysm, dilatations, ischemic complications) or treatment related side effects can occur frequently in these patients. 18-fluorodeoxyglucose positron emission tomography/computed tomography (2-[18F]FDG-PET/CT) is increasingly used to diagnose, follow, and evaluate treatment response in LVV. In this review, we aimed to summarize the current evidence on the value of 2-[18F]FDG-PET/CT for diagnosis, follow, and treatment monitoring in LVV.

show abstract

“…The PETVAS was higher in GCA than in TAK at baseline assessment. Over follow-up, the PETVAS significantly reduced with time in GCA but not in TAK [ 68 ]. A further study from this group compared various quantitative and qualitative measures of LVV activity on PET-CT in 95 patients (43 TAK, 52 GCA) over 206 visits (75 visits during active disease).…”

Section: Angiographic and Imaging Outcomes In Takmentioning

confidence: 99%

Outcome Measures and Biomarkers for Disease Assessment in Takayasu Arteritis

et al. 2022

View full text Add to dashboard Cite

Takayasu arteritis (TAK) is a less common large vessel vasculitis where histopathology of involved arteries is difficult to access except during open surgical procedures. Assessment of disease activity in TAK, therefore, relies on surrogate measures. Clinical disease activity measures such as the National Institutes of Health (NIH) score, the Disease Extent Index in TAK (DEI.TAK) and the Indian TAK Clinical Activity Score (ITAS2010) inconsistently associate with acute phase reactants (APRs). Computerized tomographic angiography (CTA), magnetic resonance angiography (MRA), or color Doppler Ultrasound (CDUS) enables anatomical characterization of stenosis, dilatation, and vessel wall characteristics. Vascular wall uptake of 18-fluorodeoxyglucose or other ligands using positron emission tomography computerized tomography (PET-CT) helps assess metabolic activity, which reflects disease activity well in a subset of TAK with normal APRs. Angiographic scoring systems to quantitate the extent of vascular involvement in TAK have been developed recently. Erythrocyte sedimentation rate and C-reactive protein have a moderate performance in distinguishing active TAK. Numerous novel biomarkers are under evaluation in TAK. Limited literature suggests a better assessment of active disease by combining APRs, PET-CT, and circulating biomarkers. Validated damage indices and patient-reported outcome measures specific to TAK are lacking. Few biomarkers have been evaluated to reflect vascular damage in TAK and constitute important research agenda.

show abstract

Longitudinal Characterization of Vascular Inflammation and Disease Activity in Takayasu Arteritis and Giant Cell Arteritis: ASingle‐CenterProspective Study

Cited by 6 publications

References 27 publications

The role of PET/CT in disease activity assessment in patients with large vessel vasculitis

The role of PET/CT in disease activity assessment in patients with large vessel vasculitis

18-Fluorodeoxyglucose positron emission tomography/computed tomography for large vessel vasculitis in clinical practice

Outcome Measures and Biomarkers for Disease Assessment in Takayasu Arteritis

Contact Info

Product

Resources

About